Zafgen to scrap lead obesity drug, shares slide - Reuters

Smarter Analyst

Zafgen to scrap lead obesity drug, shares slide Reuters Zafgen Inc said it was suspending the development of its lead obesity drug, beloranib, more than six months after the U.S. Food and Drug Administration asked the company to halt all tests on the drug following the death of two patients. Zafgen's shares ... Boston's Zafgen cuts jobs, shifts focus on obesity drugs after deaths in clinical trialsThe Boston Globe Zafgen ditches lead candidate after deaths, aims for clinic in 2017FierceBiotech Zafgen dumps beloranib for second-generation obesity candidate; cuts 34% of workforce; shares crater 42% after hoursSeeking Alpha StreetInsider.com -RTT News all 12 news articles »

from Health - Google News http://news.google.com/news/url?sa=t&fd=R&ct2=us&usg=AFQjCNGUOU3cGWrvSyXRylHj7j6EADx9ow&clid=c3a7d30bb8a4878e06b80cf16b898331&cid=52779163492686&ei=IjCPV8nGNMG53QGB3pHACA&url=http://in.reuters.com/article/us-zafgen-study-idINKCN0ZZ2PT
via IFTTT